Abstract Search

ea0070oc6.5 | Hot Topics (including COVID-19 | ECE2020

TransCon PTH, a long-acting PTH, in patients with hypoparathyroidism: Results of the phase 2 PaTH forward trial

Sikjaer Tanja , Rejnmark Lars , Khan Aliya , Schwarz Peter , Vokes Tamara , Clarke Bart , Rubin Mishaela , Hofbauer Lorenz , Eriksen Erik , Palermo Andrea , Pagotto Uberto , Marcocci Claudio , Ahmed Intekhab , Mourya Sanchita , Markova Denka , Karpf David B

Background: Hypoparathyroidism (HP) is characterized by low serum calcium (sCa) and high serum phosphate (sP). Standard of care (SoC), active vitamin D and calcium, raises sCa and sP and increases burden of illness on HP patients by worsening hypercalciuria and the CaxP product. Parathyroid hormone (PTH)(1–84)(t1/2 ~2–3 hrs) is approved and can raise sCa and allow partial withdrawal of SoC, but does not sufficiently control urine calcium or symptoma...

0 shares

ea0073oc6.6 | Oral Communications 6: Calcium and Bone | ECE2021

TransCon PTH as a potential hormone replacement therapy for patients with hypoparathyroidism: PaTH forward open-label extension trial week 26 results

Schwarz Peter , Rejnmark Lars , Rubin Mishaela , Vokes Tamara J. , Clarke Bart L. , Ahmed Intekhab , Palermo Andrea , Marcocci Claudio , Pagotto Cristina , Eriksen Erik , Mourya Sanchita , Markova Denka , Pihl Susanne , Shu Aimee , Beckert Michael , Khan Aliya

BackgroundHypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH), resulting in hypocalcemia, hyperphosphatemia, hypercalciuria, and a reduced quality of life (QoL). PTH replacement therapy should restore physiologic levels of PTH and restore downstream physiologic levels of calcitriol, promoting independence from Ca and active vitamin D supplements and normalization of QoL. TransCon PTH is an investigational long-acting p...

0 shares

Endocrine Abstracts

TransCon PTH, a long-acting PTH, in patients with hypoparathyroidism: Results of the phase 2 PaTH forward trial

TransCon PTH as a potential hormone replacement therapy for patients with hypoparathyroidism: PaTH forward open-label extension trial week 26 results

BiosciAbstracts